PIK3CA and neoplasm: Results obtained (besides confirming the lack of response to cetuximab in CRC cells bearing such mutations) showed that gabexate mesilate was able to exert a broad antitumoral effect in such cells, being able to significantly affect the cell viability, invasive potential and tumour-induced angiogenesis in all the cell lines tested in this study, including those ones harbouring dual KRAS/PIK3CA or BRAF/PIK3CA mutation.